Navigation Links
The New Affymetrix GeneChip Scanner 3000

on. The data for all SLR comparisons showed equivalence in the GeneChip Scanner 3000 and GeneArray 2500 performance.

The comparisons in Figure 6 are the most challenging because the target spike concentrations of 0.75 pM and 1.50 pM are close to the limit of detection of the assay. The average SLR ranges for 0.75 pM versus 1.50 pM were 0.61-0.70 and 0.57-0.69 for the GeneChip Scanner 3000 and GeneArray 2500, respectively. The average SLR ranges for 1.50 pM versus 3.00 pM were 0.79-0.85 and 0.81-0.84 for the GeneChip Scanner 3000 and GeneArray 2500, respectively. These values of

Conclusion

The results for human genome probe arrays described in this Technical Note clearly indicate that the performance of the GeneChip Scanner 3000 is equivalent to or better than the performance of the GeneArray 2500. Where statistical analysis was applied, Students t-tests provided substantial evidence of performance equivalence of the two scanner types. In the subset of cases where a bias may have been indicated, most favored the performance of the GeneChip Scanner 3000.

At Affymetrix, we take pride in the high quality of products we develop and support. We are pleased to Conclusion AFFYMETRIX UK Ltd Voyager, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe HP10 0HH United Kingdom Tel: +44 (0)1628 552550 Fax: +44 (0)1628 552585 saleseurope@affymetrix.com supporteurope@affymetrix.com www.affymetrix.com AFFYMETRIX, INC. 3380 Central Expressway Santa Clara, CA 95051 USA Tel: 1-888-362-2447 (1-888-DNA-CHIP) Fax: 1-408-731-5441 sales@affymetrix.com support@affymetrix.com For research use only. Not for use in diagnostic procedures. Part No. 701218 Rev. 1 2003 Affymetrix, Inc. All rights reserved. Affymetrix,GeneChip, , , , HuSNP, Jaguar, EASI, MicroDB, GenFlex
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Fine Tuning Your Data Analysis: Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms
2. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
3. GeneChip Sample Cleanup Module for cleanup of cDNA and in vitro transcribed cRNA
4. New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The New Affymetrix GeneChip Scanner

(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
(Date:7/30/2015)... 30, 2015 According to a ... Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, ... Clinical Trial), by End Users - Global Forecast to ... to reach USD 2,107.99 million by 2020 from USD ... Browse more than 75 ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Reportlinker.com announces that a new ... its catalogue: DNA ... Purchase Plans and The Impact of ... http://www.reportlinker.com/p0681348/DNA-Microarray-Market-Trends-Installed-Base-Applications-Purchase-Plans-and-The-Impact-of-Next-Gen-Sequencing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic DNA ...
... Novartis announced today new pivotal Phase III data showing ... (SJIA) were able to substantially reduce their use of ... of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1]. ... primary endpoints, will be presented on November 9th at ...
... Jennerex, Inc., a private clinical-stage biotherapeutics company focused ... oncolytic products for cancer, today presented final data from ... in patients with advanced liver cancer showing a statistically ... dose group versus the low dose group.  The final ...
Cached Biology Technology:DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 2DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 3DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 4DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 5DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 6DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 7DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 8DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 9Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 2Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 3Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 5Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 6Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 7Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 3Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 4Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 5Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 6
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... VIB and Ghent University, both in Flanders, Belgium, is ... worth 750 000 euro. The Krber Foundation annually awards ... Friml gets the prize for his research into the ... the genetic, molecular and cellular processes that direct the ...
... have discovered components of the bovine mastitis-causing bacterium, Streptococcus ... This discovery could lead the way to finally developing a ... nearly 200M per year, requires the large scale use of ... A solution to this problem will be an important contribution ...
... the world,s largest living reptile - the estuarine crocodile - ... by huge stretches of ocean despite being a poor swimmer ... ecologists. Publishing their new study in the British Ecological Society,s ... a surfer catching a wave, the crocodiles ride ocean currents ...
Cached Biology News:VIB-UGent scientist Jiri Friml receives Koerber European Science Award 2010 2New discovery could aid development of elusive bovine mastitis vaccine 2Crocodiles ride ocean currents for ocean travel 2Crocodiles ride ocean currents for ocean travel 3
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
... The CHEMICON® CaspaTag™ Pan-Caspase In Situ ... detection of active caspases in cells undergoing ... only. Not for use in diagnostic or ... Assay Kits use a novel approach to ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
Biology Products: